Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712–1723

Article  CAS  PubMed  Google Scholar 

Mahajan A, Brunson A, Adesina O, Keegan THM, Wun T (2022) The incidence of cancer-associated thrombosis is increasing over time. Blood Adv 6(1):307–320

Article  PubMed  PubMed Central  Google Scholar 

Fernandes CJ, Morinaga LTK, Alves JL, Castro MA, Calderaro D, Jardim CVP et al (2019) Cancer-associated thrombosis: the when, how and why. Eur Respir Rev 28(151):180119

Article  PubMed  PubMed Central  Google Scholar 

Samuelson Bannow BT, Lee A, Khorana AA, Zwicker JI, Noble S, Ay C et al (2018) Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 16(6):1246–1249

Article  CAS  PubMed  Google Scholar 

Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382(17):1599–1607

Article  CAS  PubMed  Google Scholar 

Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight Heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017–2023

Article  CAS  PubMed  Google Scholar 

(2013) Edoxaban versus Warfarin for the treatment of symptomatic venous thromboembolism. New Engl J Med 369(15):1406–1415

Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C et al (2022) 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334–e347

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O’Connell C et al (2018) Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 16(9):1891–1894

Article  CAS  PubMed  Google Scholar 

Kahale LA, Hakoum MB, Tsolakian IG, Alturki F, Matar CF, Terrenato I et al (2018) Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006650.pub5

Article  PubMed  PubMed Central  Google Scholar 

Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF et al (2015) Tinzaparin vs Warfarin for treatment of acute venous thromboembolism in patients with active cancer. JAMA 314(7):677

Article  CAS  PubMed  Google Scholar 

Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M et al (2003) Low-molecular-weight Heparin versus a Coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153

Article  CAS  PubMed  Google Scholar 

World Health Organisation (2019) International Statistical Classification of Diseases and Related Health Problems 10th Revision. ICD-10

Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119–2126

Article  CAS  PubMed  Google Scholar 

Khorana AA, Dalal M, Lin J, Connolly GC (2013) Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 119(3):648–655

Article  CAS  PubMed  Google Scholar 

Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F et al (2021) Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137(14):1959–1969

Article  CAS  PubMed  Google Scholar 

Faiz AS, Khan I, Beckman MG, Bockenstedt P, Heit JA, Kulkarni R et al (2015) Characteristics and risk factors of cancer associated venous thromboembolism. Thromb Res 136(3):535–541

Article  CAS  PubMed  PubMed Central  Google Scholar 

Monreal M, Falga C, Valdes M, Suarez C, Gabriel F, Tolosa C et al (2006) Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 4(9):1950–1956

Article  CAS  PubMed  Google Scholar 

Blom JW (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6):715

Article  CAS  PubMed  Google Scholar 

Puurunen MK, Gona PN, Larson MG, Murabito JM, Magnani JW, O’Donnell CJ (2016) Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb Res 145:27–33

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turpie A, Haas S, Weitz J, Ageno W, Angchaisuksiri P, Bounameaux H et al (2017) GARFIELD-VTE: 6-month outcomes. Res Pract Thromb Haemost 1:1–15

Google Scholar 

Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M (2013) Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res. 131(1):24–30

Article  CAS  PubMed  Google Scholar 

Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana A et al (2016) International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 17:452–466

Article  Google Scholar 

Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H et al (2016) Antithrombotic therapy for VTE disease. Chest 149(2):315–352

Article  PubMed  Google Scholar 

Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI et al (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J Clin Oncol 33(6):654–656

Article  CAS  PubMed  PubMed Central  Google Scholar 

McBane RD, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 18(2):411–421

Article  CAS  PubMed  Google Scholar 

El MM, Hassan A, Algaby AZ (2021) Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular 29(5):745–750

Article  CAS  PubMed  Google Scholar 

Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615–624

Article  CAS  PubMed  Google Scholar 

Planquette B, Bertoletti L, Charles-Nelson A, Laporte S, Grange C, Mahé I et al (2022) Rivaroxaban vs dalteparin in cancer-associated thromboembolism. Chest 161(3):781–790

Article  CAS  PubMed  Google Scholar 

Coleman CI, Caroti KS, Abdelgawwad K, Psaroudakis G, Fatoba S, Rivera M et al (2023) Effectiveness and safety of Rivaroxaban and low molecular weight heparin in cancer-associated venous thromboembolism. JACC CardioOncol 5(2):189–200

Article  PubMed  PubMed Central  Google Scholar 

Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI et al (2023) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 41(16):3063–3071

Article  CAS  PubMed  Google Scholar 

Li A, Garcia DA, Lyman GH, Carrier M (2019) Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res 173:158–163

Article  CAS  PubMed  Google Scholar